Connect with us

Technology

Artificial Intelligence in Drug Discovery Market to Hit USD 6.89 Billion by 2029 with 29.9% CAGR | MarketsandMarkets™

Published

on

DELRAY BEACH, Fla., Nov. 12, 2024 /PRNewswire/ — The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 billion in 2024, at a CAGR of 29.9% from 2024  to 2029. The rising shift towards integrating AI for understanding diseases and small molecule design and optimization use cases augments the growth of the market. AI tools play a major role in accelerating target identification, optimizing lead compound selection, and predicting drug efficacy and toxicity. Supervised methods such as regression, decision trees, and neural networks help predict material properties and drug candidate profiles. In contrast, unsupervised techniques such as clustering algorithms (k-means and hierarchical clustering) and dimensionality reduction identify hidden trends, patterns, and groupings in data, aiding in novel drug discovery. Deep Learning is employed to predict molecular properties, design new compounds, and other applications. Convolutional Neural Networks (CNNs) and Recurrent Neural Networks (RNNs) are more commonly used for handling complex data, such as sequences or molecular structures. Generative Adversarial Networks (GANs) are utilized to generate de novo or novel drug candidates, molecular structure simulation, and lead optimization. These tools help streamline processes, as well as reduce the time and cost involved in screening, optimizing, and discovering new drug candidates.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=151193446

Browse in-depth TOC on “Artificial Intelligence in Drug Discovery Market”

270 – Tables
50 – Figures
350 – Pages

Based on therapeutic area, the artificial intelligence (AI) in drug discovery market is segmented into oncology, infectious diseases, neurology, metabolic diseases, cardiovascular diseases, immunology, mental health, and others (respiratory diseases, nephrology, dermatological diseases, genetic disorders, inflammatory diseases, and gastrointestinal). The neurology segment held the fastest market share in the Al drug discovery market due to the increasing number of neurological disorders and the difficulties associated with drug discovery in this field, The use of Al technologies accelerates drug development because neurological diseases such as Parkinson’s, Alzheimer’s, and multiple sclerosis are difficult to diagnose and treat.

According to the WHO, in 2021, neurological conditions affected over 3 billion people worldwide. This emphasizes the need for innovative healthcare solutions. Al-powered drug discovery platforms work well in neurology, allowing faster and more accurate analysis of complex neurological data to identify potential drug candidates. The increasing availability of large datasets from clinical trials, genomics, neuroimaging, and electronic health records (EHR) records, as well as the growth investments in neurology, also contribute to market growth. In 2023, venture investments in neurology companies were USD 1.14 billion in the US. Resources like the Alzheimer’s Disease Neuroimaging Initiative (ADNI) provide vast data for machine learning applications.

Based on the process, artificial intelligence (AI) in drug discovery market is broadly classified into target identification & selection, target validation, hit identification & prioritization, hit-to-lead identification/lead generation, lead optimization, and candidate selection & validation. Hit-to-lead identification/lead generation accounts for the largest process segment in this market; it is also expected to register the highest growth owing to its critical role in streamlining the early stages of the drug development process. AI can significantly reduce the number of compounds and experiments required to find and optimize leads. This procedure uses Al algorithms to analyse large datasets, such as chemical libraries and biological interactions, to identify potential drug candidates or hits and develop them into viable leads. AI helps address long design-make-test cycles across discovery journeys. Faster screening and better exploration of vast chemical libraries are fuelling market growth for AI solutions for hit-to-lead identification/lead generation. For example, activity prediction enables more targeted experiments, and predictive analytics can help forecast compound properties. However, the lack of existing clinical data for a new molecule can hinder market growth.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=151193446

There are several opportunities in AI in drug discovery market such as growing biotech industry, emerging markets, AI in single cell experiments, Growing demand for precision medicine and personalized medicine. Key players in the artificial intelligence (AI) in drug discovery are NVIDIA Corporation (US), Exscientia (UK), Google (US), BenevolentAI (UK), Recursion (US), Insilico Medicine (US), Schrödinger, Inc. (US), Microsoft (US), Atomwise Inc. (US), Illumina, Inc. (US), Valo Health (US) among others. These players not only have a comprehensive and diverse product portfolio but also a strong geographic presence.

The key players in this market can tap these opportunities to enhance and improve their product offerings and develop innovative AI solutions for various processes, use cases, and end users. Moreover, these companies can integrate AI in drug design and optimization, understanding diseases, drug repurposing, single-cell analysis, and identification of biomarkers, disease types, and subtypes. Additionally, key players invest in AI algorithms that can examine complicated data and interpret disease mechanisms and pathways. Collaborations and partnerships between key players continue to grow rapidly, which in turn has accelerated the development of targeted therapies and contributed to rapidly expanding drug pipelines.

These market players have offered a diverse range of products and services and have operations worldwide with a major focus on North America. They rely on technological advancements to avail themselves of innovative end-to-end solutions, software, and services and increase their global footprint. These players focus on product launches and enhancements, investments, partnerships, collaborations, agreements, joint ventures, funding, acquisitions, expansions, conferences, FDA clearances, sales contracts, alliances, and other recent developments to expand their global reach and develop AI in drug discovery solutions.

NVIDIA Corporation:

NVIDIA Corporation, a prominent technology company, has made remarkable advances in artificial intelligence (AI), particularly drug discovery. NVIDIA GPUs power AI workloads in drug discovery applications such as molecular modeling, simulation, and machine learning. Nvidia’s AI software includes development tools, libraries, and frameworks that can be used to build and deploy AI applications for drug discovery. The company provides generative AI platforms like BioNeMo and Clara Discovery. NVIDIA BioNeMo simplifies the deployment of AI models, hastening the transition to AI-driven drug discovery. It offers models for 3D protein structure prediction, molecule generation, property predictions, and molecular docking. Users can customize AI models with their data, access pre-trained models, and integrate them into drug discovery workflows. NVIDIA Clara Discovery is a software suite that includes a variety of tools for AI-driven drug discovery.

NVIDIA Corporation operates more than 50 offices across the Americas, Asia, and Europe, along with manufacturing facilities in the US and Taiwan. The company collaborates with several pharmaceutical companies and biotech startups to develop solutions for AI-driven drug discovery. For example, in November 2023, NVIDIA collaborated with Genentech to improve computational models and incorporate generative AI into drug discovery processes, allowing for faster exploration of molecular designs.

Insilico Medicine:

Insilico Medicine is an end-to-end generative AI-driven biotech company accelerating drug discovery and development to treat cancer and age-related diseases. Its proprietary Pharma.AI platform spans biology, chemistry, and clinical development. The company pioneered the application of reinforcement learning and generative adversarial networks (GANs) to develop new molecular structures for diseases with known and unknown targets. Its products and services are used by pharmaceutical companies, biotechnology companies, and academic research institutions. Insilico Medicine has produced a diversified internal pipeline of 31 programs for 29 drug targets. The company’s lead drug is ISM001-055, a small-molecule chemical drug candidate primarily designed to treat fibrosis-related indications, including idiopathic pulmonary fibrosis. The company has offices in the US, Hong Kong, Canada, and the UAE. The company has more than 150 academic and industrial collaborations worldwide. For instance, in September 2024, Insilico Medicine collaborated with Inimmune to leverage its proprietary AI platform, Chemistry42, in accelerating the discovery and development of next generation immunotherapeutic.

Exscientia:

Exscientia is an AI-driven small-molecule drug discovery and design company. The company designed and developed an end-to-end solution of AI and experimental technologies for target identification, drug candidate design, translational models, and patient selection. The company’s patient-first AI process comprises four elements, namely, Precision Target (experimental and literature-based AI systems to prioritize projects), Precision Design (an extensive platform of AI technologies to design innovative drugs), Precision Experiment (tech-enabled precision experimentation to derive better data), and Precision Medicine (integrated analysis of patient data to ensure clinical relevance). The platform has helped design candidate drug molecules that have progressed into clinical trials and improve disease understanding through AI-guided assessment and generative AI. Exscientia collaborates with pharmaceutical companies such as GSK, Sanofi, and Roche. The company has offices in the UK, the US, and Japan. For instance, in July 2024, Exscientia announced the expansion of its collaboration with Amazon Web Services, Inc. to utilize AWS’s AI and machine learning services, further enhancing its end-to-end drug discovery and automation platform.

For more information, Inquire Now!

Related Reports:

Microscopy Market

Synthetic Biology Market

Metagenomic Sequencing Market

Proteomics Market

Digital Pathology Market

Get access to the latest updates on Artificial Intelligence in Drug Discovery Companies and Artificial Intelligence in Drug Discovery Market Size

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg

View original content:https://www.prnewswire.co.uk/news-releases/artificial-intelligence-in-drug-discovery-market-to-hit-usd-6-89-billion-by-2029-with-29-9-cagr–marketsandmarkets-302302221.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Cineverse Podcast Network Expands with Midnight Pulp and RetroCrush Audio Series, and New True Crime Show Creepy Places

Published

on

By

New Shows Join Top-10 Podcast Network as it Celebrates Record Growth Driven by Popular Horror Lineup Under the BloodyFM Sub-brand

LOS ANGELES, Nov. 25, 2024 /PRNewswire/ — Cineverse Podcast Network, the audio division of next-gen entertainment studio Cineverse (Nasdaq: CNVS), has today announced a major expansion that goes well beyond its horror roots. Now home to popular entertainment, true crime and horror podcasts, the Cineverse Podcast Network is well-positioned to build upon its recent success.

In fact, Cineverse has grown its podcast revenue 98% during the fiscal quarter that ended Sept. 30 year over year and 60% from the previous quarter. The Cineverse Podcast Network also recorded 15 million downloads and listens in October, setting a new monthly record.

Among the drivers of this growth is Creepy Places: A True Crime Podcast, which recently launched via a partnership between Cineverse’s fan-first horror brand Bloody Disgusting and host Jon Grilz. The popular show at the intersection of true crime and historical hauntings has attracted 1.3 million monthly downloads since premiering in September and joins other additions to Cineverse’s growing podcast portfolio:

The iconic horror brand Dead Meat brings its dedicated fan base and over 200 episodes to Cineverse with the recently signed Dead Meat Podcast, hosted by Chelsea Rebecca and James A. Janisse, creators of the Dead Meat YouTube channel with over 6.6 million subscribers.Extending Cineverse’s popular action/cult movie streaming brand of the same name, Midnight Pulp will premiere in 2025. Hosted by Diana Prince, who plays “Darcy the Mail Girl” on Shudder’s top series The Last Drive-in with Joe Bob Briggs, each episode of the podcast will explore an entry from the streaming video channel, with Prince taking questions from listeners on everything from relationship advice to movie recommendations.Following a soft launch earlier this year, RetroCrush is Cineverse’s first official podcast created for anime fans. Hosts Malcolm Crawford, C2 and “it’s Eman” – three well-known anime fans – explore the hidden gems and popular shows featured on Cineverse’s RetroCrush streaming channel in weekly episodes.

“From partnering with talent and IP that come with pre-existing fan bases, to leveraging our owned-and-operated brands like Bloody Disgusting, Midnight Pulp and RetroCrush – all part of the company through strategic acquisitions from the past few years – we have quietly built one of the industry’s top podcast networks,” said Cineverse President and Chief Strategy Officer Erick Opeka. “Creators and partners – including advertisers, platforms and studios – are seeing this success and now coming to us to explore opportunities to work together in audio, and we are well-positioned to grow even further in the new year.”

These new podcasts follow other recently released shows on the Cineverse Podcast Network:

Mayfair Watchers Society: The chart-topping fiction podcast returned in May with Season 2, featuring 24 episodes every other week. Created in partnership with Trevor Henderson, the author of Scarewaves and prominent horror artist, the series brings Henderson’s creatures to life and features a full cast, original music and immersive sound design.Nightmare Soup: The horror fiction anthology podcast also premiered earlier this year, taking listeners back to their favorite horror stories from childhood. Inspired by iconic books like Scary Stories to Tell in the Dark and Goosebumps, the 10-episode series airs every other Sunday.

Now home to more than 50 shows and ranking among the top 10 podcast networks by audience, the Cineverse Podcast Network has set the stage for significant ad sales growth over the next few quarters.

ABOUT CINEVERSE

On a mission to uplift storytellers and entertain fans with the power of technology, Cineverse  (NASDAQ: CNVS) distributes over 71,000 premium films, series, and podcasts. Engaging over 150 million unique monthly users, Cineverse delivers more than one billion minutes of curated content each month – connecting fans with stories that resonate.

With properties like the box office sensation Terrifier 3, iconic horror destination Bloody Disgusting, the Bob Ross Channel, women’s entertainment channel Dove, and a leading podcast network, Cineverse is the first stop for audiences seeking authentic and experiential content. From a vibrant range of content and fandom channels, to next-gen advertising offerings and streaming solutions, Cineverse is setting the stage for a new era of entertainment.

Press Contacts:

For Media
The Lippin Group for Cineverse, cineverse@lippingroup.com

For Investors
Julie Milstead, investorrelations@cineverse.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cineverse-podcast-network-expands-with-midnight-pulp-and-retrocrush-audio-series-and-new-true-crime-show-creepy-places-302315624.html

SOURCE Cineverse Corp.

Continue Reading

Technology

Neighborly Appoints Stacy Lynn Bourgeois as Chief Marketing Officer

Published

on

By

WACO, Texas, Nov. 25, 2024 /PRNewswire/ —  Neighborly®, the world’s largest home services company, today announced the appointment of Stacy Lynn Bourgeois as its new Chief Marketing Officer (CMO), effective December 2. She will serve as a member of Neighborly’s corporate leadership team and report directly to CEO Mike Davis.

Stacy Lynn brings a wide array of experience in business and brand strategy, organizational leadership, customer insight, data analytics, and marketing technology,” said Davis. “Her expertise and innovative approach to marketing will be instrumental in helping us better connect with our customers, differentiating our brands, making Neighborly and our service brands ridiculously easy to do business with while navigating an increasingly competitive landscape.”

The fanatical focus on the end consumer also serves Neighborly’s core mission of driving same-store sales growth with its franchise business owners. Bourgeois’ mixed background in both franchising and non-franchised business makes her uniquely qualified to deliver for both our customers, end-consumers, and franchise business owners.

Bourgeois is a strategic marketer who has driven double-digit growth while compiling a breadth of experiences. Throughout her career, she has launched new physical and digital products as well as a new restaurant concept at Yum! brands, stood up several new teams such as performance marketing and data science, implemented a new marketing technology stack, and led Pizza Hut through an agency review and countless creative campaigns.

She joins Neighborly from Amazon, where she broadened her scope from marketing to business more holistically in roles such as Global Head of Product, Quality & Operations for Amazon Renewed or U.S. Head of Musical Instruments. In her time with Amazon, she’s enhanced the discoverability of preowned products, increased conversion rates, simplified customer experience, improved operations, and owned a multibillion-dollar P&L. Even in general management-focused roles, she’s anchored on driving growth through the customer – such as offering free lessons with an instrument purchase on Amazon.

I am thrilled to be joining the incredible team at Neighborly and support our franchise owners,” said Bourgeois. “Customers invite Neighborly and our brands into their homes, which is deeply personal and requires tremendous trust. My goal is to earn this trust by listening to and innovating for customers in a way that builds lasting relationships with our amazing brands.”

Bourgeois will be based in Irving, Texas.

About Neighborly®

Neighborly® is the world’s largest home services company with more than 30 brands and 5,500 franchises collectively serving 14 million+ customers by repairing, maintaining, and enhancing their homes and businesses. Through Neighborly.com and the Neighborly mobile app, we connect consumers to local service providers that meet rigorous franchisor standards across 19 service categories. More information about Neighborly, and its franchise concepts, is available at Neighborlybrands.com. To learn about franchising opportunities with Neighborly, click here.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neighborly-appoints-stacy-lynn-bourgeois-as-chief-marketing-officer-302315116.html

SOURCE Neighborly

Continue Reading

Technology

EHA Highlights Commitment to Innovation and Collaboration at ASH Annual Meeting

Published

on

By

THE HAGUE, Netherlands, Nov. 25, 2024 /PRNewswire/ — The European Hematology Association (EHA) will showcase its dedication to advancing research and fostering collaboration at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition from December 7-10, 2024, in San Diego, California, USA.

The partnership between EHA and ASH is testament to both organizations’ commitment to progress and improving patient care. The EHA-ASH Joint Symposium, scheduled for Sunday, December 8 from 12:30-13:30 (PDT), will focus on myelodysplastic syndromes, showcasing expert insights from Amy DeZern of Johns Hopkins University and Matteo Della Porta of Humanitas Cancer Center. EHA President Antonio Almeida remarked, “The collaboration between EHA and ASH holds immense significance for the global medical community. Both organizations serve as pivotal platforms for advancing the understanding, research, education, and treatment of blood disorders. […] By combining our strengths, together, we can enhance research, education, advocacy, and patient care, generating significant benefits that resonate across nations and communities.” This joint session is another milestone in a fruitful collaboration that continues to shape the future of hematology.

In 2024, EHA reached unprecedented levels of engagement, connecting more professionals than ever. Membership surged by 25%, bringing EHA’s community to over 8,300 members, and the EHA2024 Congress attracted a record-breaking 17,900 delegates. This growth reflects EHA’s commitment to a member-focused approach, empowering professionals to exchange knowledge, collaborate on research, and share best practices on a global scale.

HemaSphere, EHA’s peer-reviewed journal, has recently achieved a significant milestone with a 2023 Impact Factor of 11.9, ranking it seventh among hematology journals globally. This development is a testament to the high-quality, cutting-edge research that HemaSphere publishes and its value to the hematology community.

With a vision for “Borderless Hematology,” EHA will continue to drive global connectivity, innovation, and excellence.

ASH delegates are invited to learn about EHA at booth #300.

About EHA

The European Hematology Association (EHA) is a membership organization serving a community of over 8,000 medical professionals, researchers, and scientists with an active interest in hematology. EHA is the largest Europe-based organization connecting hematologists worldwide and supports career development and research, harmonizes hematology education, and advocates for hematologists and hematology.

Website: www.ehaweb.org

“Towards prevention, cure, and quality of life for all patients with blood disorders”.

Logo – https://mma.prnewswire.com/media/2461261/4811631/European_Hematology_Association_Logo.jpg 

View original content:https://www.prnewswire.com/news-releases/eha-highlights-commitment-to-innovation-and-collaboration-at-ash-annual-meeting-302313636.html

SOURCE European Hematology Association (EHA)

Continue Reading

Trending